|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **PEG3350+E (n=48)** | | | **PEG4000 (n=49)** | | |  |
|  | Events (n) | Subjects with event (n) | % of subjects | Events (n) | Subjects with event  (n) | % of subjects | p |
| **Drug-related adverse events** |  |  |  |  |  |  |  |
| * abdominal pain | 0 | 0 | 0% | 1 | 1 | 2% | 1.00 |
| * diarrhoea | 0 | 0 | 0% | 1 | 1 | 2% | 1.00 |
| * nausea | 2 | 2 | 4% | 0 | 0 | 0% | 0.24 |
| * vomiting | 1 | 1 | 2% | 1 | 1 | 2% | 1.00 |
| * nasopharyngitis | 0 | 0 | 0% | 1 | 1 | 2% | 1.00 |
| * headache | 0 | 0 | 0% | 1 | 1 | 2% | 1.00 |
| **TOTAL** | 3 | 3 | 6% | 5 | 3 | 6% | 1.00 |
|  |  |  |  |  |  |  |  |
| **Serious adverse events** |  |  |  |  |  |  |  |
| * dehydration | 2 | 1 | 2% | 0 | 0 | 0% | 0.49 |
| * upper respiratory infection | 1 | 1 | 2% | 0 | 0 | 0% | 0.49 |
| * metabolic acidosis | 1 | 1 | 2% | 0 | 0 | 0% | 0.49 |
| * constipation | 1 | 1 | 2% | 0 | 0 | 0% | 0.49 |
| **TOTAL** | 5 | 2 | 4% | 0 | 0 | 0% | 0.24 |

**Suppl Table 4.** All drug-related adverse events and serious adverse events (ITT population).